To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small
This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.
| Condition(s) | Non-Small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC. |
| Who can participate | Inclusion Criteria: * The patient must be at least 18 years old * Karnofsky Performance Status \> 80 * NSCLC confirmed by cytology or histology; for subjects who cannot safely obtain pathological evidence due to factors such as tumor lesion location, patient's underlying diseases, or high puncture risk, after unanimous consent of the multidisciplinary team (MDT) discussion, they meet the clinical diagnostic criteria for NSCLC based on typical imaging features (such as enhanced chest CT and/or PET/CT) combined with clinical manifestations; * Early-stage tumors are defined as T1 (≤3cm) N0M0 based on enhanced computed tomography (CT) and positron emission tomography (PET) * The tumor must be more than 2 cm away from the proximal bronchial tree in all directions (the proximal bronchial tree is |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Anhui Provincial Cancer Hospital |
| Locations | Hefei, Anhui, China |
| Start date | 2025-09-20 |
| NCT ID | NCT07195084 |
| Official listing | https://clinicaltrials.gov/study/NCT07195084 |